Latest Commercialization News

Maas Group Holdings reported FY25 underlying EBITDA of $219.4 million, matching guidance, with a robust 97% cash conversion and an 8% increase in dividends. The company’s Construction Materials division drove growth despite challenges in Civil Construction.

Metallium Limited has secured exclusive lease options for two fully permitted U.S. sites, advancing its strategy to deploy its Flash Joule Heating technology across multiple states. This move complements its flagship Texas campus and positions the company for rapid scale-up in the growing e-waste metal recovery sector.

Brambles Limited reported a solid FY25 with a 3% rise in sales revenue and a 10% increase in underlying profit, alongside progress on sustainability targets and a renewed board.

VEEM Ltd reported a 15% revenue decline in FY25 amid rising costs and COVID impacts but showed a robust second-half recovery and secured a significant $65 million defence contract renewal.

VEEM Ltd posted a 15% revenue decline and a 57% net profit drop for FY25, reflecting cyclical defence contract impacts. The company secured a $65 million ASC contract extension and continues investing in R&D and automation to drive future growth.

Octava Minerals reports impressive initial bioleaching recoveries of critical rare earth elements and lithium from its Byro Project, highlighting a promising, low-cost extraction pathway.

Athena Resources has produced a 10kg sample of ultra-high-grade magnetite concentrate grading 70.55% iron from its Byro Magnetite Project, positioning the company at the forefront of green steel feedstock supply.

Finbar Group reports a resilient FY25 with a 16% rise in underlying profit and a robust $1 billion development pipeline, underpinned by strong sales and strategic focus.

Auckland International Airport reported a 12% revenue increase to NZD 1 billion and a 12% rise in underlying profit, driven by growing passenger numbers and strong commercial performance. The airport is progressing a major infrastructure program while achieving significant emissions reductions.

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

LDR Assets Pty Ltd, part of the Lederer Family Office, has initiated an off-market takeover offer for all stapled securities in the Elanor Commercial Property Fund at a 5.3% premium to recent prices. The bid signals a potential overhaul of ECF’s management and governance.

Invion Limited secures a pivotal FDA Orphan Drug Designation for its lead candidate INV043, targeting anal cancer with promising preclinical results and a fast-tracked development path.